We perform an econometric investigation of the contribution of pharmaceutical innovation to mortality reduction and … pharmaceutical innovation, there would have been no increase and perhaps even a small decrease in mean age at death, and that new … drugs have increased life expectancy, and lifetime income, by about 0.75-1.0% per annum. The drug innovation measures are …

models using annual U.S. time-series data on life expectancy, health expenditure, and medical innovation. Reliable annual … data are available for only one type of innovation - new drugs - but pharmaceutical R&D accounts for a significant fraction … innovation (in the form of new drug approvals) and expenditure on medical care (especially public expenditure) contributed to …

innovation literature. Using an NPE-derived dataset with patent-specific revenues we find that the relationship of citations to … behind it. We attempt to explain this relationship with a simple model of innovation, allowing for both productive and … findings have important implications for our basic understanding of growth, innovation, and intellectual property policy. …

innovation-led growth into the Chamley-Judd framework, using a Schumpeterian growth model where productivity … on the market size for innovation. At the same time, for a given labor supply, taxing capital also reduces innovation …

We build a model of firm-level innovation, productivity growth and reallocation featuring endogenous entry and exit. A …